Is Bausch Health Stock a Good Investment?
Bausch Health Investment Advice | BHC |
- Examine Bausch Health's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bausch Health's leadership team and their track record. Good management can help Bausch Health navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Bausch Health's business and its evolving consumer preferences.
- Compare Bausch Health's performance and market position to its competitors. Analyze how Bausch Health is positioned in terms of product offerings, innovation, and market share.
- Check if Bausch Health pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bausch Health's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bausch Health Companies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bausch Health Companies is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Solid | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bausch Health Stock
Researching Bausch Health's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 77.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.63. Bausch Health Companies recorded a loss per share of 0.48. The entity last dividend was issued on the 10th of November 2010. The firm had 2:1 split on the 16th of October 2000.
To determine if Bausch Health is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bausch Health's research are outlined below:
| Bausch Health appears to be risky and price may revert if volatility continues | |
| The company reported the last year's revenue of 8.76 B. Reported Net Loss for the year was (611 M) with profit before taxes, overhead, and interest of 5.76 B. | |
| Bausch Health has a strong financial position based on the latest SEC filings | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance |
Bausch Health uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bausch Health Companies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bausch Health's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bausch Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bausch Health's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1997-02-27 | 1996-12-31 | 0.06 | 0.07 | 0.01 | 16 | ||
2001-04-26 | 2001-03-31 | 0.18 | 0.2 | 0.02 | 11 | ||
1996-07-17 | 1996-06-30 | 0.04 | 0.06 | 0.02 | 50 | ||
1996-04-17 | 1996-03-31 | 0.03 | 0.05 | 0.02 | 66 | ||
2004-08-04 | 2004-06-30 | 0.24 | 0.28 | 0.04 | 16 | ||
2004-04-29 | 2004-03-31 | 0.13 | 0.18 | 0.05 | 38 | ||
2003-07-29 | 2003-06-30 | 0.47 | 0.52 | 0.05 | 10 | ||
2001-08-01 | 2001-06-30 | 0.25 | 0.3 | 0.05 | 20 |
Bausch Health Target Price Consensus
Bausch target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Bausch Health's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Hold |
Most Bausch analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Bausch stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Bausch Health Companies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBausch Health Target Price Projection
Bausch Health's current and average target prices are 9.13 and 9.67, respectively. The current price of Bausch Health is the price at which Bausch Health Companies is currently trading. On the other hand, Bausch Health's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Bausch Health Market Quote on 13th of November 2024
Target Price
Analyst Consensus On Bausch Health Target Price
Bausch Health Analyst Ratings
Bausch Health's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Bausch Health stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Bausch Health's financials, market performance, and future outlook by experienced professionals. Bausch Health's historical ratings below, therefore, can serve as a valuable tool for investors.Know Bausch Health's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bausch Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bausch Health Companies backward and forwards among themselves. Bausch Health's institutional investor refers to the entity that pools money to purchase Bausch Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mizuho Markets Americas Llc | 2024-09-30 | 7 M | Laurion Capital Management Lp | 2024-06-30 | 6.5 M | Mfn Partners Management, Lp | 2024-06-30 | 6 M | Goldman Sachs Group Inc | 2024-06-30 | 5.4 M | Kohlberg Kravis Roberts & Co Lp | 2024-06-30 | 5.2 M | Arrowstreet Capital Limited Partnership | 2024-06-30 | 4.2 M | Norges Bank | 2024-06-30 | 3.8 M | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 3.3 M | Dimensional Fund Advisors, Inc. | 2024-06-30 | 3.2 M | Icahn Carl C | 2024-06-30 | 34.7 M | Paulson & Company Inc | 2024-06-30 | 26.4 M |
Bausch Health's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.44 B.Market Cap |
|
Bausch Health's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.06) | (0.06) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | 0.58 | 0.61 |
Determining Bausch Health's profitability involves analyzing its financial statements and using various financial metrics to determine if Bausch Health is a good buy. For example, gross profit margin measures Bausch Health's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bausch Health's profitability and make more informed investment decisions.
Bausch Health's Earnings Breakdown by Geography
Please note, the presentation of Bausch Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bausch Health's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bausch Health's management manipulating its earnings.
Evaluate Bausch Health's management efficiency
Bausch Health Companies has Return on Asset of 0.0415 % which means that on every $100 spent on assets, it made $0.0415 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (23.0454) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.61, whereas Return On Tangible Assets are projected to grow to (0.06). At present, Bausch Health's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 2.7 B, whereas Total Assets are forecasted to decline to about 14.9 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.22) | (0.21) | |
| Tangible Book Value Per Share | (48.56) | (50.99) | |
| Enterprise Value Over EBITDA | 10.87 | 10.32 | |
| Price Book Value Ratio | (2.86) | (2.72) | |
| Enterprise Value Multiple | 10.87 | 10.32 | |
| Price Fair Value | (2.86) | (2.72) | |
| Enterprise Value | 27.3 B | 17.6 B |
Examining the leadership quality of Bausch Health Companies offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 0.745 |
Basic technical analysis of Bausch Stock
As of the 13th of November 2024, Bausch Health shows the Downside Deviation of 1.62, risk adjusted performance of 0.2222, and Mean Deviation of 1.93. Bausch Health Companies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bausch Health's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bausch Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bausch Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bausch Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bausch Health's Outstanding Corporate Bonds
Bausch Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bausch Health Companies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bausch bonds can be classified according to their maturity, which is the date when Bausch Health Companies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Bausch Health's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bausch Health's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.2222 | |||
| Market Risk Adjusted Performance | (87.19) | |||
| Mean Deviation | 1.93 | |||
| Semi Deviation | 1.01 | |||
| Downside Deviation | 1.62 | |||
| Coefficient Of Variation | 358.26 | |||
| Standard Deviation | 3.0 | |||
| Variance | 9.02 | |||
| Information Ratio | 0.2229 | |||
| Jensen Alpha | 0.8299 | |||
| Total Risk Alpha | 0.208 | |||
| Sortino Ratio | 0.4136 | |||
| Treynor Ratio | (87.20) | |||
| Maximum Drawdown | 17.92 | |||
| Value At Risk | (1.96) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 2.62 | |||
| Semi Variance | 1.02 | |||
| Expected Short fall | (2.49) | |||
| Skewness | 2.16 | |||
| Kurtosis | 6.42 |
| Risk Adjusted Performance | 0.2222 | |||
| Market Risk Adjusted Performance | (87.19) | |||
| Mean Deviation | 1.93 | |||
| Semi Deviation | 1.01 | |||
| Downside Deviation | 1.62 | |||
| Coefficient Of Variation | 358.26 | |||
| Standard Deviation | 3.0 | |||
| Variance | 9.02 | |||
| Information Ratio | 0.2229 | |||
| Jensen Alpha | 0.8299 | |||
| Total Risk Alpha | 0.208 | |||
| Sortino Ratio | 0.4136 | |||
| Treynor Ratio | (87.20) | |||
| Maximum Drawdown | 17.92 | |||
| Value At Risk | (1.96) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 2.62 | |||
| Semi Variance | 1.02 | |||
| Expected Short fall | (2.49) | |||
| Skewness | 2.16 | |||
| Kurtosis | 6.42 |
Consider Bausch Health's intraday indicators
Bausch Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bausch Health stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 71835.04 | |||
| Daily Balance Of Power | (0.54) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 9.11 | |||
| Day Typical Price | 9.11 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.22) |
Bausch Health Corporate Filings
8K | 1st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 1st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of September 2024 Other Reports | ViewVerify |
Bausch Stock media impact
Far too much social signal, news, headlines, and media speculation about Bausch Health that are available to investors today. That information is available publicly through Bausch media outlets and privately through word of mouth or via Bausch internal channels. However, regardless of the origin, that massive amount of Bausch data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bausch Health news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bausch Health relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bausch Health's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bausch Health alpha.
Bausch Health Companies Historical Investor Sentiment
Investor biases related to Bausch Health's public news can be used to forecast risks associated with an investment in Bausch. The trend in average sentiment can be used to explain how an investor holding Bausch can time the market purely based on public headlines and social activities around Bausch Health Companies. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bausch Health's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bausch Health and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Bausch Health news discussions. The higher the estimate score, the more favorable the investor's outlook on Bausch Health.
Bausch Health Corporate Directors
| Sarah Kavanagh | Independent Director | Profile | |
| Richard Schutter | Independent Director | Profile | |
| Amy Wechsler | Independent Director | Profile | |
| Robert Power | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bausch Health's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.